| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Cílem studie bylo hodnocení kardiotoxicity během myeloablativního přípravného režimu a transplantace krvetvorných buněk pomocí biomarkerů srdečního poškození: glykogenfosforyláza BB (GPBB), mastné kyseliny vázající protein (H-FABP), kardiální troponiny T (cTnT, cTnI), kreatinkináza MB (CK-MB mass), myoglobin. Ve studii bylo devatenáct pacientů (průměrný věk 42,8+-10,0 let, 13 mužů) sakutní leukemií. Naše výsledky naznačují, že GPBB uvolňovaný zkardiomyocytů v peritransplantačním období by mohl být novým markerem akutní subklinické kardiotoxicity. Předpovědní hodnota pro rozvoj kardiomyopatie je nejasná a v této souvislosti budou potřeba další studie. (cs)
- The aim of the study was to assess cardiac toxicity during myeloablative preparative regimen (PR) and hematopoietic cell transplantation (HCT) with biomarkers of cardiac injury: glycogen phosphorylase BB (GPBB), heart fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Nineteen patients (mean age 42.8+-10.0 years, 13 males) with acute leukemia were studied. GPBB became elevated (above 7.30 µg/L) in 5 (26.3%) patients after PR, remained elevated in 5 (26.3%) after HCT and in 1 (5.3%) 14 days after HCT. Other markers remained within the reference range in all patients. Our findings suggest that GPBB released from cardiomyocytes after myeloablative PR followed by HCT could be a new marker of acute subclinical cardiotoxicity. The predictive value for development of cardiomyopathy is unclear and further studies will be needed in this context.
- The aim of the study was to assess cardiac toxicity during myeloablative preparative regimen (PR) and hematopoietic cell transplantation (HCT) with biomarkers of cardiac injury: glycogen phosphorylase BB (GPBB), heart fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Nineteen patients (mean age 42.8+-10.0 years, 13 males) with acute leukemia were studied. GPBB became elevated (above 7.30 µg/L) in 5 (26.3%) patients after PR, remained elevated in 5 (26.3%) after HCT and in 1 (5.3%) 14 days after HCT. Other markers remained within the reference range in all patients. Our findings suggest that GPBB released from cardiomyocytes after myeloablative PR followed by HCT could be a new marker of acute subclinical cardiotoxicity. The predictive value for development of cardiomyopathy is unclear and further studies will be needed in this context. (en)
|
| Title
| - Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation
- Glykogenfosforyláza BB jako marker srdečního poškození při vysokodávkové chemoterapii během transplantace krvetvorných buněk. (cs)
- Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation (en)
|
| skos:prefLabel
| - Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation
- Glykogenfosforyláza BB jako marker srdečního poškození při vysokodávkové chemoterapii během transplantace krvetvorných buněk. (cs)
- Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation (en)
|
| skos:notation
| - RIV/00216208:11150/07:00003642!RIV08-MO0-11150___
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - Z(MO0FVZ0000503), Z(MZ0FNHK2005)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11150/07:00003642
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - cardiac biomarkers; cardiac toxicity; GPBB; high-dose chemotherapy (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| |
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)